title: Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem.
abstract: Stenotrophomonas maltophilia (S. maltophilia) has recently emerged as an important nosocomial pathogen. Treatment of invasive infections caused by this organism is difficult as the bacterium is frequently resistant to a wide range of commonly used antimicrobials. Trimethoprim-sulfamethoxazole (TMP - SXT) is recommended as the agent of choice for the treatment of S. maltophilia infections. However, the development of resistance to this antibiotic represents a real challenge to laboratorians and clinicians. This letter describes the first isolation of S. maltophilia resistant to TMP - SXT from two patients treated at Riyadh Armed Forces Hospital which is a major tertiary hospital in Saudi Arabia.
authors.affiliation: Department of Microbiology, Armed Forces Hospital, Box X-966, P.O. Box 7897, Riyadh - 11159, Saudi Arabia. asjass2002@yahoo.com
authors.forename: Asma Marzouq
authors.initials: AM
authors.lastname: Al-Jasser
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy*; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012529:Saudi Arabia; D012772:Shock, Septic / Q000209:etiology; D020615:Stenotrophomonas maltophilia / Q000187:drug effects*; D013420:Sulfamethoxazole / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome; D014295:Trimethoprim / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D014295:Trimethoprim; D013420:Sulfamethoxazole